Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

Time from definitive therapy to onset of metastatic disease predicts outcomes in men with metastatic hormone sensitive prostate cancer.

Hahn AW, Stenehjem DD, Alex AB, Gill DM, Cheng HH, Kessler ER, Chittoria N, Twardowski P, Vaishampayan U, Agarwal N.

Urol Oncol. 2019 Feb 13. pii: S1078-1439(19)30050-X. doi: 10.1016/j.urolonc.2019.01.029. [Epub ahead of print]

PMID:
30770300
2.

Docetaxel-related toxicity in metastatic hormone-sensitive and metastatic castration-resistant prostate cancer.

Schweizer MT, Gulati R, Mostaghel EA, Nelson PS, Montgomery RB, Yu EY, Cheng HH.

Med Oncol. 2016 Jul;33(7):77. doi: 10.1007/s12032-016-0793-1. Epub 2016 Jun 14.

3.

Hormone naïve metastatic prostate cancer: How to treat it?

Østergren PB, Ternov KK, Jensen CFS, Jakobsen H, Lindberg H, Sønksen J, Fode M.

Arch Esp Urol. 2019 Mar;72(2):192-202.

PMID:
30855021
4.

Time of metastatic disease presentation and volume of disease are prognostic for metastatic hormone sensitive prostate cancer (mHSPC).

Francini E, Gray KP, Xie W, Shaw GK, Valença L, Bernard B, Albiges L, Harshman LC, Kantoff PW, Taplin ME, Sweeney CJ.

Prostate. 2018 Sep;78(12):889-895. doi: 10.1002/pros.23645. Epub 2018 Apr 29.

PMID:
29707790
5.

Adding abiraterone to androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer: A systematic review and meta-analysis.

Rydzewska LHM, Burdett S, Vale CL, Clarke NW, Fizazi K, Kheoh T, Mason MD, Miladinovic B, James ND, Parmar MKB, Spears MR, Sweeney CJ, Sydes MR, Tran N, Tierney JF; STOPCaP Abiraterone Collaborators.

Eur J Cancer. 2017 Oct;84:88-101. doi: 10.1016/j.ejca.2017.07.003. Epub 2017 Aug 8. Review.

6.

Contemporary Management of the Newly Diagnosed Prostate Cancer Patient with Metastatic Disease at Presentation.

Xu L, Pachynski RK.

Curr Urol Rep. 2018 Aug 13;19(10):79. doi: 10.1007/s11934-018-0835-7. Review.

PMID:
30105573
7.

Survival benefit, disease progression and quality-of-life outcomes of abiraterone acetate plus prednisone versus docetaxel in metastatic hormone-sensitive prostate cancer: A network meta-analysis.

Feyerabend S, Saad F, Li T, Ito T, Diels J, Van Sanden S, De Porre P, Roiz J, Abogunrin S, Koufopoulou M, Fizazi K.

Eur J Cancer. 2018 Nov;103:78-87. doi: 10.1016/j.ejca.2018.08.010. Epub 2018 Sep 12.

8.

Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naïve Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial.

Lavaud P, Gravis G, Foulon S, Joly F, Oudard S, Priou F, Latorzeff I, Mourey L, Soulié M, Delva R, Krakowski I, Laguerre B, Théodore C, Ferrero JM, Beuzeboc P, Habibian M, Rolland F, Deplanque G, Pouessel D, Zanetta S, Berdah JF, Dauba J, Baciuchka M, Platini C, Linassier C, Tubiana-Mathieu N, Machiels JP, Kouri CE, Ravaud A, Suc E, Eymard JC, Hasbini A, Bousquet G, Culine S, Boher JM, Tergemina-Clain G, Legoupil C, Fizazi K.

Eur Urol. 2018 May;73(5):696-703. doi: 10.1016/j.eururo.2017.09.022. Epub 2017 Oct 23.

PMID:
29074061
9.

The evolving landscape of metastatic hormone-sensitive prostate cancer: a critical review of the evidence for adding docetaxel or abiraterone to androgen deprivation.

McNamara M, Sweeney C, Antonarakis ES, Armstrong AJ.

Prostate Cancer Prostatic Dis. 2018 Sep;21(3):306-318. doi: 10.1038/s41391-017-0014-9. Epub 2017 Dec 20. Review.

PMID:
29263421
10.

Optimal sequencing of docetaxel and abiraterone in men with metastatic castration-resistant prostate cancer.

Maughan BL, Xhou XC, Suzman DL, Nadal R, Bassi S, Schweizer MT, Antonarakis ES.

Prostate. 2015 Nov;75(15):1814-20. doi: 10.1002/pros.23064. Epub 2015 Aug 26.

PMID:
26306637
11.

Treatment selection for men with metastatic prostate cancer who progress on upfront chemo-hormonal therapy.

Barata P, Emamekhoo H, Mendiratta P, Koshkin V, Tyler A, Ornstein M, Rini BI, Gilligan T, Kyriakopoulos C, Garcia JA.

Prostate. 2018 Sep;78(13):1035-1041. doi: 10.1002/pros.23663. Epub 2018 Jun 7.

PMID:
29882332
12.

Abiraterone acetate for early stage metastatic prostate cancer: patient selection and special considerations.

Castellan P, Marchioni M, Castellucci R, De Francesco P, Iantorno R, Schips L, Cindolo L.

Ther Clin Risk Manag. 2018 Dec 6;14:2341-2347. doi: 10.2147/TCRM.S159824. eCollection 2018. Review.

13.

[Abiraterone plus prednisone in patients with newly diagnosed high-risk metastatic hormone-sensitive prostate cancer (mHSPC)].

Miller K.

Aktuelle Urol. 2019 Mar 27. doi: 10.1055/a-0852-3405. [Epub ahead of print] German.

PMID:
30919390
14.

EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.

Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, Mason M, Matveev V, Wiegel T, Zattoni F, Mottet N; European Association of Urology.

Eur Urol. 2014 Feb;65(2):467-79. doi: 10.1016/j.eururo.2013.11.002. Epub 2013 Nov 12. Review.

PMID:
24321502
15.

Novel androgen axis systemic therapies for metastatic hormone-sensitive prostate cancer.

Hahn AW, Hale P, Rathi N, Agarwal N.

Curr Opin Urol. 2017 Nov;27(6):559-565. doi: 10.1097/MOU.0000000000000443. Review.

PMID:
28816716
16.
17.
18.
19.

Taxane chemotherapy vs antiandrogen agents as first-line therapy for metastatic castration-resistant prostate cancer.

Sonpavde G, Huang A, Wang L, Baser O, Miao R.

BJU Int. 2018 Jun;121(6):871-879. doi: 10.1111/bju.14152. Epub 2018 Mar 6.

PMID:
29388324
20.

Addition of abiraterone, docetaxel, bisphosphonate, celecoxib or combinations to androgen-deprivation therapy (ADT) for metastatic hormone-sensitive prostate cancer (mHSPC): a network meta-analysis.

Tan PS, Aguiar P Jr, Haaland B, Lopes G.

Prostate Cancer Prostatic Dis. 2018 Nov;21(4):516-523. doi: 10.1038/s41391-018-0055-8. Epub 2018 Jun 6.

PMID:
29875432

Supplemental Content

Support Center